Yarchoan M - Search Results

1

Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials.

Sidiropoulos DN, Stein-O'Brien GL, Danilova L, Gross NE, Charmsaz S, Xavier S, Leatherman J, Wang H, Yarchoan M, Jaffee EM, Fertig EJ, Ho WJ. Sidiropoulos DN, et al. Among authors: yarchoan m. JCI Insight. 2022 Oct 10;7(19):e160398. doi: 10.1172/jci.insight.160398. JCI Insight. 2022. PMID: 36214223 Free PMC article.

2

Targeting neoantigens to augment antitumour immunity.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Yarchoan M, et al. Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24. Nat Rev Cancer. 2017. PMID: 28233802 Free PMC article. Review.

3

Strategies for Increasing Pancreatic Tumor Immunogenicity.

Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Johnson BA 3rd, et al. Among authors: yarchoan m. Clin Cancer Res. 2017 Apr 1;23(7):1656-1669. doi: 10.1158/1078-0432.CCR-16-2318. Clin Cancer Res. 2017. PMID: 28373364 Free PMC article. Review.

4

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M. Yarchoan M, et al. Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237. Oncotarget. 2017. PMID: 28454122 Free PMC article.

5

Targeting neoantigens to augment antitumour immunity.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Yarchoan M, et al. Nat Rev Cancer. 2017 Aug 24;17(9):569. doi: 10.1038/nrc.2017.74. Nat Rev Cancer. 2017. PMID: 28835723 No abstract available.

6

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQM, Forde PM. Anagnostou V, et al. Among authors: yarchoan m. Clin Cancer Res. 2017 Sep 1;23(17):4959-4969. doi: 10.1158/1078-0432.CCR-16-3065. Clin Cancer Res. 2017. PMID: 28864724 Free PMC article.

7

Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.

Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA. Yarchoan M, et al. Clin Cancer Res. 2017 Dec 1;23(23):7333-7339. doi: 10.1158/1078-0432.CCR-17-0950. Epub 2017 Sep 19. Clin Cancer Res. 2017. PMID: 28928158 Free PMC article.

8

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Yarchoan M, Hopkins A, Jaffee EM. Yarchoan M, et al. N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444. N Engl J Med. 2017. PMID: 29262275 Free PMC article. No abstract available.

9

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.

Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman SA. Diehl A, et al. Among authors: yarchoan m. Oncotarget. 2017 Dec 14;8(69):114268-114280. doi: 10.18632/oncotarget.23217. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371985 Free PMC article.

10

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM. Hopkins AC, et al. Among authors: yarchoan m. JCI Insight. 2018 Jul 12;3(13):e122092. doi: 10.1172/jci.insight.122092. JCI Insight. 2018. PMID: 29997287 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters